Xcout Intel
TargED Biopharmaceuticals
TargED Biopharmaceuticals is a Netherlands-based biotechnology company that develops first-class biological drugs to improve the treatment of thrombosis. The company utilizes small antibodies to deliver enzymes directly to blood clots, aiming to provide targeted thrombolysis for patients suffering from various thrombotic disorders.
Subscribe to see TargED Biopharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
TargED Biopharmaceuticals at a glance
TargED Biopharmaceuticals is a biotechnology company headquartered in Netherlands. Xcout tracks 4 named people at TargED Biopharmaceuticals, including Coen Maas (Co-founder).
TargED Biopharmaceuticals leadership
- Coen MaasCo-founder
- Kristof VercruysseCo-founder
- Marc van MoorselCo-founder
- Steven de MaatCo-founder
TargED Biopharmaceuticals competitors
A few of TargED Biopharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Acticor Biotech is a clinical-stage biopharmaceutical company headquartered in Paris, France, that specializes in developing innovative treatments for acute thrombotic diseases.
River BioMedics is a Dutch biotechnology company headquartered in Enschede, Netherlands, founded in 2018. The company focuses on cardiovascular drug discovery by utilizing proprietary 3D human engineered heart tissue models to address unmet medical needs.
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Repair Biotechnologies develops a proprietary Cholesterol Degrading Platform to treat medical conditions caused by localized cholesterol accumulations. Its primary focus is creating therapies that rapidly reduce atherosclerotic plaque in arteries to combat cardiovascular disease.
AAVantgarde Bio is an Italian biotechnology company developing adeno-associated virus (AAV) gene therapies for rare genetic diseases, including conditions caused by genes too large to fit into a single AAV vector. Its technology uses dual-AAV approaches to deliver larger therapeutic genes, serving patients with serious inherited disorders and the clinicians who treat them.
Get TargED Biopharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on TargED Biopharmaceuticals in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access